310 related articles for article (PubMed ID: 28502091)
21. Belatacept Rescue Therapy in Kidney Transplant Recipients With Vascular Lesions: A Case Control Study.
Bertrand D; Cheddani L; Etienne I; François A; Hanoy M; Laurent C; Lebourg L; Le Roy F; Lelandais L; Loron MC; Godin M; Guerrot D
Am J Transplant; 2017 Nov; 17(11):2937-2944. PubMed ID: 28707779
[TBL] [Abstract][Full Text] [Related]
22. Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly.
Vincenti F; Blancho G; Durrbach A; Grannas G; Grinyó J; Meier-Kriesche HU; Polinsky M; Yang L; Larsen CP
Am J Transplant; 2017 Dec; 17(12):3219-3227. PubMed ID: 28758341
[TBL] [Abstract][Full Text] [Related]
23. Alemtuzumab induction and belatacept maintenance in marginal pathology renal allografts.
Sparkes T; Ravichandran B; Opara O; Ugarte R; Drachenberg CB; Philosophe B; Bromberg JS; Barth RN
Clin Transplant; 2019 Jun; 33(6):e13531. PubMed ID: 30866104
[TBL] [Abstract][Full Text] [Related]
24. An Acute Cellular Rejection With Detrimental Outcome Occurring Under Belatacept-Based Immunosuppressive Therapy: An Immunological Analysis.
de Graav GN; Hesselink DA; Dieterich M; Kraaijeveld R; Douben H; de Klein A; Roelen DL; Weimar W; Roodnat JI; Clahsen-van Groningen MC; Baan CC
Transplantation; 2016 May; 100(5):1111-9. PubMed ID: 26599491
[TBL] [Abstract][Full Text] [Related]
25. Selective Costimulation Blockade With Antagonist Anti-CD28 Therapeutics in Transplantation.
Vanhove B; Poirier N; Soulillou JP; Blancho G
Transplantation; 2019 Sep; 103(9):1783-1789. PubMed ID: 30951014
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
Wen X; Casey MJ; Santos AH; Hartzema A; Womer KL
Am J Transplant; 2016 Nov; 16(11):3202-3211. PubMed ID: 27137884
[TBL] [Abstract][Full Text] [Related]
27. Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression.
Lo DJ; Weaver TA; Stempora L; Mehta AK; Ford ML; Larsen CP; Kirk AD
Am J Transplant; 2011 Jan; 11(1):22-33. PubMed ID: 21070604
[TBL] [Abstract][Full Text] [Related]
28. Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation.
Zhang H; Wang Z; Zhang J; Gui Z; Han Z; Tao J; Chen H; Sun L; Fei S; Yang H; Tan R; Chandraker A; Gu M
Front Immunol; 2021; 12():618737. PubMed ID: 33732243
[TBL] [Abstract][Full Text] [Related]
29. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.
Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
Am J Transplant; 2018 Jul; 18(7):1783-1789. PubMed ID: 29509295
[TBL] [Abstract][Full Text] [Related]
30. Belatacept during pregnancy in renal transplant recipients: Two case reports.
Combs J; Kagan A; Boelkins M; Coscia L; Moritz M; Hofmann RM
Am J Transplant; 2018 Aug; 18(8):2079-2082. PubMed ID: 29719109
[TBL] [Abstract][Full Text] [Related]
31. Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro.
Cvetkovski F; Razavi R; Sellberg F; Berglund E; Berglund D
Am J Transplant; 2023 Oct; 23(10):1603-1611. PubMed ID: 37270108
[TBL] [Abstract][Full Text] [Related]
32. Prevention of acute rejection after rescue with Belatacept by association of low-dose Tacrolimus maintenance in medically complex kidney transplant recipients with early or late graft dysfunction.
Gallo E; Abbasciano I; Mingozzi S; Lavacca A; Presta R; Bruno S; Deambrosis I; Barreca A; Romagnoli R; Mella A; Fop F; Biancone L
PLoS One; 2020; 15(10):e0240335. PubMed ID: 33057374
[TBL] [Abstract][Full Text] [Related]
33. Obesity is associated with a higher incidence of rejection in patients on belatacept: A pooled analysis from the BENEFIT/BENEFIT-EXT clinical trials.
Lange NW; King K; Husain SA; Salerno DM; Tsapepas DS; Hedvat J; Yu M; Mohan S
Am J Transplant; 2024 Jun; 24(6):1027-1034. PubMed ID: 38387620
[TBL] [Abstract][Full Text] [Related]
34. Selective CD28 blockade attenuates CTLA-4-dependent CD8+ memory T cell effector function and prolongs graft survival.
Liu D; Badell IR; Ford ML
JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321374
[TBL] [Abstract][Full Text] [Related]
35. Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients.
Wojciechowski D; Chandran S; Vincenti F
Clin Transplant; 2017 May; 31(5):. PubMed ID: 28190259
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients.
Sethi S; Najjar R; Peng A; Choi J; Lim K; Vo A; Jordan SC; Huang E
Transplantation; 2020 Jul; 104(7):1500-1507. PubMed ID: 31568398
[TBL] [Abstract][Full Text] [Related]
37. A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation.
de Graav GN; Baan CC; Clahsen-van Groningen MC; Kraaijeveld R; Dieterich M; Verschoor W; von der Thusen JH; Roelen DL; Cadogan M; van de Wetering J; van Rosmalen J; Weimar W; Hesselink DA
Transplantation; 2017 Oct; 101(10):2571-2581. PubMed ID: 28403127
[TBL] [Abstract][Full Text] [Related]
38. T Cell Subsets Predicting Belatacept-Resistant Rejection: Finding the Root Where the Trouble Starts.
Wekerle T
Am J Transplant; 2017 Sep; 17(9):2235-2237. PubMed ID: 28613437
[No Abstract] [Full Text] [Related]
39. Donor-Derived Regulatory Dendritic Cell Infusion Maintains Donor-Reactive CD4
Ezzelarab MB; Lu L; Shufesky WF; Morelli AE; Thomson AW
Front Immunol; 2018; 9():250. PubMed ID: 29520267
[TBL] [Abstract][Full Text] [Related]
40. Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT.
Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
Am J Transplant; 2018 Jul; 18(7):1774-1782. PubMed ID: 29573335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
